Filing summary
Entity and period: The supplied filing is IsoRay, Inc.’s Form 10-Q, not a filing identified as Perspective Therapeutics, Inc. It reports the quarter ended September 30, 2012, IsoRay’s first quarter of fiscal 2013; comparative results are for the quarter ended September 30, 2011. The interim statements are unaudited.
Financial results and position
| Metric | Quarter ended September 30, 2012 | Comparable 2011 quarter |
|---|---|---|
| Product sales | $1.056 million | $1.213 million |
| Gross profit (loss) | $(20,425); (2)% margin | $66,342; 5% margin |
| Operating loss | $(1.123) million | $(1.102) million |
| Net loss | $(993,668) | $(1.102) million |
| Net loss attributable to common shareholders | $(996,326), or $(0.03) per share | $(1.105) million, or $(0.04) per share |
| Cash used in operating activities | $(938,629) | $(542,086) |
At September 30, 2012, cash and cash equivalents were $5.029 million, total current assets were $6.496 million, and total current liabilities were $578,385. Total liabilities were $1.504 million, including a $740,717 asset retirement obligation and a $185,000 warrant derivative liability. The filing reports no conventional borrowing balance. Cash increased by $2.356 million during the quarter, principally reflecting $3.292 million in net proceeds from a July 2012 registered stock offering. The company had 34,597,717 common shares outstanding as of November 6, 2012.
Changes versus the prior period
- Sales declined 13%. Prostate product sales fell 20% to $881,856; brain and GliaSite sales contributed $24,574 and $60,804, respectively, while lung sales fell 32% to $64,100.
- Cost of product sales declined 6%, but less than revenue, turning the prior-year gross profit into a gross loss. Management attributed the pressure to lower prostate sales and costs associated with GliaSite RTS.
- Research and development expense declined 44% to $141,472; operating expenses overall fell 6%. The operating loss nevertheless widened slightly.
- Net loss improved, in part because the company recorded $129,000 of noncash income from a decrease in the fair value of its warrant liability.
- Operating cash use rose to $938,629. Management said the prior-year period included an IRS grant-receivable collection and that operating cash use would have been materially similar after adjusting for it.
Outlook, commentary and risks
Management estimated cash and cash equivalents of approximately $4.83 million on November 9, 2012 and said this would fund anticipated operating and capital needs for at least 12 months, assuming revenue and expenses remain at current levels. It expected fiscal 2013 capital expenditures below $200,000 and approximately $200,000 in protocol expenses, while noting that unanticipated spending or changes in revenue and collections could affect these estimates.
Management’s plan to approach breakeven relies on growing sales to existing and new customers, expanding GliaSite RTS sales and developing additional treatment applications while controlling costs. It cautioned that profitability and revenue growth are not assured. The prostate market has continued to decline; newer applications are early-stage and sales can vary significantly with purchasing by a small number of physicians. The company may need additional financing, potentially dilutive equity financing, and funding may not be available on acceptable terms or at all.
- A know-how royalty dispute with the Lawrence Family Trust remains unresolved; the parties may demand binding arbitration.
- The company has an asset retirement obligation related to radioactive materials and facility leasehold improvements, and faces environmental and product-liability risks.
- Management reported disclosure controls were effective, but said it was continuing remediation of a material weakness and significant deficiency identified in its fiscal 2012 Form 10-K. It hired a CPA and planned further training and reviews.
- The filing reports no material changes to the risk factors in the fiscal 2012 Form 10-K and no off-balance-sheet arrangements.
Key facts for investors to verify
- Confirm the issuer and reporting period: the document is IsoRay’s quarter ended September 30, 2012, rather than a Perspective Therapeutics filing.
- Track whether declining prostate revenue is offset by sustained growth in GliaSite and other non-prostate applications.
- Assess cash burn against management’s conditional 12-month liquidity estimate, including timing of customer receipts and any financing needs.
- Monitor gross margins, operating losses and the impact of noncash warrant fair-value changes on reported earnings.
- Follow the royalty dispute and progress on remediation of the previously disclosed internal-control issues.